Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation

Han Na Kang, Jae Woo Choi, Hyo Sup Shim, Jinna Kim, Dae Joon Kim, Chang Young Lee, Min Hee Hong, Seong Yong Park, A. Young Park, Eun Joo Shin, Seo Yoon Lee, Kyoung Ho Pyo, Mi Ran Yun, Hun Mi Choi, Sung Sook Lee, Seok Young Kim, Hanna Lee, Soonmyung Paik, Byoung Chul Cho, Jin Gu LeeHye Ryun Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Preclinical models that can better predict therapeutic activity in clinical trials are needed in this era of personalized cancer treatment. Herein, we established genomically and clinically annotated patient-derived xenografts (PDXs) from non-small-cell lung cancer (NSCLC) patients and investigated whether these PDXs would faithfully recapitulate patient responses to targeted therapy. Methods: Patient-derived tumors were implanted in immunodeficient mice and subsequently expanded via re-implantation. Established PDXs were examined by light microscopy, genomic profiling, and in vivo drug testing, and the successful engraft rate was analyzed with the mutation profile, histology, or acquisition method. Finally, the drug responses of PDXs were compared with the clinical responses of the respective patients. Results: Using samples from 122 patients, we established 41 NSCLC PDXs [30 adenocarcinoma (AD), 11 squamous cell carcinoma (SQ)], among which the following driver mutation were observed: 13 EGFR-mutant, 4 ALK-rearrangement, 1 ROS1-rearrangement, 1 PIK3CA-mutant, 1 FGFR1-amplification, and 2 KRAS-mutant. We rigorously characterized the relationship of clinical features to engraftment rate and latency rates. The engraft rates were comparable across histologic type. The AD engraft rate tended to be higher for surgically resected tissues relative to biopsies, whereas similar engraft rates was observed for SQ, irrespective of the acquisition method. Notably, EGFR-mutants demonstrated significantly longer latency time than EGFR-WT (86 vs. 37days, P = 0.007). The clinical responses were recapitulated by PDXs harboring driver gene alteration (EGFR, ALK, ROS1, or FGFR1) which regressed to their target inhibitors, suggesting that established PDXs comprise a clinically relevant platform. Conclusion: The establishment of genetically and clinically annotated NSCLC PDXs can yield a robust preclinical tool for biomarker, therapeutic target, and drug discovery.

Original languageEnglish
Pages (from-to)168-178
Number of pages11
JournalLung Cancer
Volume124
DOIs
Publication statusPublished - 2018 Oct

Fingerprint

Heterografts
Non-Small Cell Lung Carcinoma
Adenocarcinoma
erbB-1 Genes
Mutation
Drug Discovery
Therapeutics
Pharmaceutical Preparations
Microscopy
Squamous Cell Carcinoma
Neoplasms
Histology
Biomarkers
Clinical Trials
Biopsy
Light

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Kang, Han Na ; Choi, Jae Woo ; Shim, Hyo Sup ; Kim, Jinna ; Kim, Dae Joon ; Lee, Chang Young ; Hong, Min Hee ; Park, Seong Yong ; Park, A. Young ; Shin, Eun Joo ; Lee, Seo Yoon ; Pyo, Kyoung Ho ; Yun, Mi Ran ; Choi, Hun Mi ; Lee, Sung Sook ; Kim, Seok Young ; Lee, Hanna ; Paik, Soonmyung ; Cho, Byoung Chul ; Lee, Jin Gu ; Kim, Hye Ryun. / Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation. In: Lung Cancer. 2018 ; Vol. 124. pp. 168-178.
@article{beeb76e52bb445adb95a3165b00a91e5,
title = "Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation",
abstract = "Background: Preclinical models that can better predict therapeutic activity in clinical trials are needed in this era of personalized cancer treatment. Herein, we established genomically and clinically annotated patient-derived xenografts (PDXs) from non-small-cell lung cancer (NSCLC) patients and investigated whether these PDXs would faithfully recapitulate patient responses to targeted therapy. Methods: Patient-derived tumors were implanted in immunodeficient mice and subsequently expanded via re-implantation. Established PDXs were examined by light microscopy, genomic profiling, and in vivo drug testing, and the successful engraft rate was analyzed with the mutation profile, histology, or acquisition method. Finally, the drug responses of PDXs were compared with the clinical responses of the respective patients. Results: Using samples from 122 patients, we established 41 NSCLC PDXs [30 adenocarcinoma (AD), 11 squamous cell carcinoma (SQ)], among which the following driver mutation were observed: 13 EGFR-mutant, 4 ALK-rearrangement, 1 ROS1-rearrangement, 1 PIK3CA-mutant, 1 FGFR1-amplification, and 2 KRAS-mutant. We rigorously characterized the relationship of clinical features to engraftment rate and latency rates. The engraft rates were comparable across histologic type. The AD engraft rate tended to be higher for surgically resected tissues relative to biopsies, whereas similar engraft rates was observed for SQ, irrespective of the acquisition method. Notably, EGFR-mutants demonstrated significantly longer latency time than EGFR-WT (86 vs. 37days, P = 0.007). The clinical responses were recapitulated by PDXs harboring driver gene alteration (EGFR, ALK, ROS1, or FGFR1) which regressed to their target inhibitors, suggesting that established PDXs comprise a clinically relevant platform. Conclusion: The establishment of genetically and clinically annotated NSCLC PDXs can yield a robust preclinical tool for biomarker, therapeutic target, and drug discovery.",
author = "Kang, {Han Na} and Choi, {Jae Woo} and Shim, {Hyo Sup} and Jinna Kim and Kim, {Dae Joon} and Lee, {Chang Young} and Hong, {Min Hee} and Park, {Seong Yong} and Park, {A. Young} and Shin, {Eun Joo} and Lee, {Seo Yoon} and Pyo, {Kyoung Ho} and Yun, {Mi Ran} and Choi, {Hun Mi} and Lee, {Sung Sook} and Kim, {Seok Young} and Hanna Lee and Soonmyung Paik and Cho, {Byoung Chul} and Lee, {Jin Gu} and Kim, {Hye Ryun}",
year = "2018",
month = "10",
doi = "10.1016/j.lungcan.2018.08.008",
language = "English",
volume = "124",
pages = "168--178",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",

}

Kang, HN, Choi, JW, Shim, HS, Kim, J, Kim, DJ, Lee, CY, Hong, MH, Park, SY, Park, AY, Shin, EJ, Lee, SY, Pyo, KH, Yun, MR, Choi, HM, Lee, SS, Kim, SY, Lee, H, Paik, S, Cho, BC, Lee, JG & Kim, HR 2018, 'Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation', Lung Cancer, vol. 124, pp. 168-178. https://doi.org/10.1016/j.lungcan.2018.08.008

Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation. / Kang, Han Na; Choi, Jae Woo; Shim, Hyo Sup; Kim, Jinna; Kim, Dae Joon; Lee, Chang Young; Hong, Min Hee; Park, Seong Yong; Park, A. Young; Shin, Eun Joo; Lee, Seo Yoon; Pyo, Kyoung Ho; Yun, Mi Ran; Choi, Hun Mi; Lee, Sung Sook; Kim, Seok Young; Lee, Hanna; Paik, Soonmyung; Cho, Byoung Chul; Lee, Jin Gu; Kim, Hye Ryun.

In: Lung Cancer, Vol. 124, 10.2018, p. 168-178.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation

AU - Kang, Han Na

AU - Choi, Jae Woo

AU - Shim, Hyo Sup

AU - Kim, Jinna

AU - Kim, Dae Joon

AU - Lee, Chang Young

AU - Hong, Min Hee

AU - Park, Seong Yong

AU - Park, A. Young

AU - Shin, Eun Joo

AU - Lee, Seo Yoon

AU - Pyo, Kyoung Ho

AU - Yun, Mi Ran

AU - Choi, Hun Mi

AU - Lee, Sung Sook

AU - Kim, Seok Young

AU - Lee, Hanna

AU - Paik, Soonmyung

AU - Cho, Byoung Chul

AU - Lee, Jin Gu

AU - Kim, Hye Ryun

PY - 2018/10

Y1 - 2018/10

N2 - Background: Preclinical models that can better predict therapeutic activity in clinical trials are needed in this era of personalized cancer treatment. Herein, we established genomically and clinically annotated patient-derived xenografts (PDXs) from non-small-cell lung cancer (NSCLC) patients and investigated whether these PDXs would faithfully recapitulate patient responses to targeted therapy. Methods: Patient-derived tumors were implanted in immunodeficient mice and subsequently expanded via re-implantation. Established PDXs were examined by light microscopy, genomic profiling, and in vivo drug testing, and the successful engraft rate was analyzed with the mutation profile, histology, or acquisition method. Finally, the drug responses of PDXs were compared with the clinical responses of the respective patients. Results: Using samples from 122 patients, we established 41 NSCLC PDXs [30 adenocarcinoma (AD), 11 squamous cell carcinoma (SQ)], among which the following driver mutation were observed: 13 EGFR-mutant, 4 ALK-rearrangement, 1 ROS1-rearrangement, 1 PIK3CA-mutant, 1 FGFR1-amplification, and 2 KRAS-mutant. We rigorously characterized the relationship of clinical features to engraftment rate and latency rates. The engraft rates were comparable across histologic type. The AD engraft rate tended to be higher for surgically resected tissues relative to biopsies, whereas similar engraft rates was observed for SQ, irrespective of the acquisition method. Notably, EGFR-mutants demonstrated significantly longer latency time than EGFR-WT (86 vs. 37days, P = 0.007). The clinical responses were recapitulated by PDXs harboring driver gene alteration (EGFR, ALK, ROS1, or FGFR1) which regressed to their target inhibitors, suggesting that established PDXs comprise a clinically relevant platform. Conclusion: The establishment of genetically and clinically annotated NSCLC PDXs can yield a robust preclinical tool for biomarker, therapeutic target, and drug discovery.

AB - Background: Preclinical models that can better predict therapeutic activity in clinical trials are needed in this era of personalized cancer treatment. Herein, we established genomically and clinically annotated patient-derived xenografts (PDXs) from non-small-cell lung cancer (NSCLC) patients and investigated whether these PDXs would faithfully recapitulate patient responses to targeted therapy. Methods: Patient-derived tumors were implanted in immunodeficient mice and subsequently expanded via re-implantation. Established PDXs were examined by light microscopy, genomic profiling, and in vivo drug testing, and the successful engraft rate was analyzed with the mutation profile, histology, or acquisition method. Finally, the drug responses of PDXs were compared with the clinical responses of the respective patients. Results: Using samples from 122 patients, we established 41 NSCLC PDXs [30 adenocarcinoma (AD), 11 squamous cell carcinoma (SQ)], among which the following driver mutation were observed: 13 EGFR-mutant, 4 ALK-rearrangement, 1 ROS1-rearrangement, 1 PIK3CA-mutant, 1 FGFR1-amplification, and 2 KRAS-mutant. We rigorously characterized the relationship of clinical features to engraftment rate and latency rates. The engraft rates were comparable across histologic type. The AD engraft rate tended to be higher for surgically resected tissues relative to biopsies, whereas similar engraft rates was observed for SQ, irrespective of the acquisition method. Notably, EGFR-mutants demonstrated significantly longer latency time than EGFR-WT (86 vs. 37days, P = 0.007). The clinical responses were recapitulated by PDXs harboring driver gene alteration (EGFR, ALK, ROS1, or FGFR1) which regressed to their target inhibitors, suggesting that established PDXs comprise a clinically relevant platform. Conclusion: The establishment of genetically and clinically annotated NSCLC PDXs can yield a robust preclinical tool for biomarker, therapeutic target, and drug discovery.

UR - http://www.scopus.com/inward/record.url?scp=85051454364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051454364&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2018.08.008

DO - 10.1016/j.lungcan.2018.08.008

M3 - Article

C2 - 30268457

AN - SCOPUS:85051454364

VL - 124

SP - 168

EP - 178

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -